Trump admin may reclassify marijuana: Would that make it legal in the US?

President Trump confirmed his administration is exploring reclassifying marijuana from a Schedule I to a Schedule III drug, a move that, while not constituting federal legalization or decriminalization, would significantly impact the cannabis industry. This reclassification would recognize marijuana's medical uses and lower abuse potential, allowing cannabis businesses to deduct expenses and potentially reduce their effective tax rates from over 70%, and also facilitate research. However, it would also subject dispensaries to DEA registration and reporting, with full federal legalization still requiring separate legislative action such as the proposed STATES 2.0 Act.

Analysis

The Trump administration's confirmation that it is reviewing the reclassification of marijuana from a Schedule I to a Schedule III substance represents a significant potential catalyst for the cannabis sector, despite the uncertain timeline. While this action would not constitute federal legalization or decriminalization, its primary financial impact would be the alleviation of the 280E tax provision. This change would permit cannabis businesses, which currently face effective tax rates often exceeding 70%, to deduct standard operating expenses like rent and payroll, fundamentally improving profitability and cash flow prospects across the industry. However, this potential upside is coupled with new regulatory hurdles. A Schedule III classification would subject thousands of dispensaries to DEA registration and stringent reporting requirements, mirroring the oversight applied to traditional pharmacies—a compliance burden the industry may find onerous and for which the DEA may be unprepared. The overall market impact remains moderated by this uncertainty and the fact that full federal de-prohibition would still require separate, and less certain, legislative action such as the proposed STATES 2.0 Act.

Key Decisions for Investors

• Monitor for a formal decision on reclassification, as a shift to Schedule III would be a material event, directly unlocking profitability for cannabis operators by eliminating the punitive 280E tax burden.
• Evaluate the operational and compliance capabilities of cannabis companies, as the benefits of reclassification would be paired with significant new costs and complexities associated with DEA registration and reporting.
• Investors should distinguish between the immediate catalyst of reclassification and the separate, longer-term prospect of full federal legalization, ensuring investment theses are not based on conflating the two distinct policy outcomes.